

AMENDMENTS TO THE CLAIMS

A listing of the claims presented in this patent application appears below. This listing replaces all prior versions and listing of claims in this patent application.

Claims 1- 19 (canceled).

20. (Previously presented) A method for inducing the re-expression of a previously silenced endogenous gene encoding human sodium/iodide symporter in a human thyroid carcinoma cell comprising administering to the cell a compound selected from the group consisting of 5-azacytodine, sodium butyrate, dimethylsulfoxide, adenosyl-1,8-diamino-3-thio-octane, and phenylacetate.

21. (Previously presented) The method of claim 20 wherein the thyroid carcinoma cell is a thyroid typical papillary carcinoma cell or a follicular carcinoma.

22. (Previously presented) The method of claim 20 wherein re-expression is effected by demethylating the previously silenced endogenous gene or by inhibiting methylation in the cell.

23. (Previously presented) A method for restoring iodide transport to a human thyroid carcinoma cell comprising administering 5-azacytodine to the cell in an amount effective to transcriptionally activate the expression of a gene encoding the human sodium/iodide symporter.

24 (Previously presented) A method of restoring iodide transport to a human thyroid carcinoma cell comprising administering difluoromethylornithine or S-adenosyl-1,8-diamino-3-thio-octane to the cell in an amount effective to transcriptionally activate the expression of a gene encoding the human sodium/iodide symporter.